Time filter

Source Type

Guildford, United Kingdom

Muscogiuri G.,Futura Medical | Colao A.,University of Naples Federico II
Archives of Toxicology | Year: 2016

Phtalates are commonly found in several household products such as food packaging, furniture and toys. Humans are exposed to phtalates through different ways such as inhalation, ingestion and dermal contact. Due to the abundance of plastic in our society, the exposure to phtalates is ubiquitous. A growing body of evidence investigated the association of phtalate exposure with cardiovascular risk factors, i.e., obesity, type 2 diabetes and hypertension. Phtalates are thought to contribute to obesity through their binding and activation of PPARγ receptor that in turn results in the upregulation of adipocyte production. Phtalates are also known to interfere with insulin signaling and to increase oxidative stress. All these mechanisms contribute to the onset of insulin resistance. Recent evidences support a role of phtalates in the pathogenesis of atherosclerosis and hypertension. Thus, the aim of this communication was to summarize the current evidences dealing with the association of phtalates and cardiovascular risk factors. © 2016 Springer-Verlag Berlin Heidelberg

Brunner M.,Medical University of Vienna | Davies D.,Futura Medical | Martin W.,Pharmakin GmbH | Leuratti C.,CROSS S.A. | And 2 more authors.
British Journal of Clinical Pharmacology | Year: 2011

AIMS: To evaluate the relative plasma and tissue availability of diclofenac after repeated topical administration of a novel diclofenac acid-based delivery system under development (DCF100C). METHODS: This was a single-centre, open-label, three-period, crossover clinical trial of five discrete diclofenac formulations. Test preparations comprised two concentrations (1.0% and 2.5%) of DCF100C, with and without menthol and eucalyptus oil (total daily doses of 5mg and 12.5mg). Voltaren® Emulgel® gel (1.0%) was the commercially available comparator (total daily dose of 40mg). Topical application was performed onto the thigh of 20 male healthy subjects for 3 days. Applying a Youden square design, each drug was evaluated in 12 subjects, with each subject receiving three test preparations. Blood sampling and in vivo microdialysis in subcutaneous adipose and skeletal muscle tissues were performed for 10h after additional final doses on the morning of day 4. RESULTS: All four DCF100C formulations demonstrated a three- to fivefold, dose-dependent increase in systemic diclofenac availability compared with Voltaren® Emulgel® and were approximately 30-40 times more effective at facilitating diclofenac penetration through the skin, taking different dose levels into account. Tissue concentrations were low and highly variable. The 2.5% DCF100C formulation without sensory excipients reached the highest tissue concentrations. AUC(0,10h) was 2.71 times greater than for Voltaren® Emulgel® (90% CI 99.27, 737.46%). Mild erythema at the application site was the most frequent adverse event associated with DCF100C. There were no local symptoms after treatment with the reference formulation. CONCLUSION: DCF100C formulations were safe and facilitated greater diclofenac penetration through the skin compared with the commercial comparator. DCF100C represents a promising alternative to oral and topical diclofenac treatments that warrants further development. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Futura Medical | Date: 2014-03-04

There is provided a condom having a coating or deposit of a composition which includes a physiologically-active agent such as glyceryl trinitrate, wherein the condom has been treated with a neutralising or acidic material such that the condom, when immersed in water, results in the water having a pH of 7 or less. The condom may be treated with an acidic slurry of dusting powder. Also provided is a process for the manufacture of condoms, in which the process includes the steps of: 1) treating the formed condoms with a neutralising or acidic material; and 2) thereafter applying to the condoms a composition including a physiologically-active agent such as glyceryl trinitrate, wherein the condoms, when immersed in water, results in the water having a pH of 7 or less.

Futura Medical | Date: 2010-11-10

A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.

Futura Medical | Date: 2015-12-08

Contraceptive apparatus; condoms.

Discover hidden collaborations